Investor Presentaiton

Cardiovascular milvexian Camzyos MYK-224 TKR study demonstrates a differentiated monotherapy profile: Supports moving into AF Monotherapy 30% AXIOMATIC-TKR study¹ Major bleeding CRNM 0.25 0.236 ■ All VTE + all death 0.214 25% 0.209 20% 15% 0.113 0.09 0.076 AXIOMATIC-TKR 1 Phase 2 data Efficacy Robust efficacy with superiority vs enoxaparin Safety No major bleeds observed in milvexian arms 0.065 10% Dose Response 5% 0.014 0 0.014 0.007 0.007 0 0.013 0.007 in bleeding observed from existing anticoagulants Clear efficacy & no dose response distinct 0.003 0 0 0 0 0 0 0 0% 40 mg QD 25 mg BID 50 mg BID 100 mg BID 200 mg BID 25 mg QD 50 mg QD 200 mg QD Supports Phase 3 AF trial Enoxaparin milvexian Milvexian has potential to offer comparable/better efficacy with reduced bleed risk to a broader range of patients Ill Bristol Myers Squibb™ 1. Weitz J, et al. N Engl J Med. 2021; 385:2161-2172. Not for Product Promotional Use 115

View entire presentation